These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34493086)

  • 21. Nitinol Stent Versus Bypass in Long Femoropopliteal Lesions: 2-Year Results of a Randomized Controlled Trial.
    Enzmann FK; Nierlich P; Aspalter M; Hitzl W; Dabernig W; Hölzenbein T; Ugurluoglu A; Seitelberger R; Linni K
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2541-2549. PubMed ID: 31786218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.
    Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D
    J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
    Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
    Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-Expanding Nitinol Stent vs Percutaneous Transluminal Angioplasty in the Treatment of Femoropopliteal Lesions: 3-Year Data From the SM-01 Trial.
    Iida O; Urasawa K; Komura Y; Soga Y; Inoue N; Hara H; Yajima J; Nakamura S; Ohki T; Ando H; Hirano K; Horita Y; Kichikawa K; Yokoi Y; Miyamoto A; Nakamura M; Takahara M; Mano T; Nanto S
    J Endovasc Ther; 2019 Apr; 26(2):158-167. PubMed ID: 30702021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship Between Primary Patency and Lesion Length Following Bare Nitinol Stent Placement for Femoropopliteal Disease.
    Soga Y; Takahara M; Iida O; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Yamaoka T; Ando K
    J Endovasc Ther; 2015 Dec; 22(6):862-7. PubMed ID: 26438352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
    Park SH; Rha SW; Choi CU; Kim EJ; Oh DJ; Cho YH; Choi WG; Lee SJ; Kim YH; Choi SH; Kim WH; Kim KC; Cho JH; Kim JH; Kim SM; Bae JH; Bong JM; Kang WY; Baek JY; Seo JB; Chung WY; Park MW; Her SH; Suh J; Kim MW; Kim YJ; Choi HJ; Soh JW;
    Trials; 2014 Sep; 15():355. PubMed ID: 25208688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective Multicenter Comparison of S.M.A.R.T. CONTROL and MISAGO Stents in Treatment of Femoropopliteal Lesions.
    Suzuki K; Takahara M; Shintani Y; Tanaka A; Soga Y; Yamaoka T; Tosaka A; Sasaki S; Kawasaki D; Tsuchiya T; Kozuki A; Iida O
    J Vasc Interv Radiol; 2016 Nov; 27(11):1642-1649. PubMed ID: 27567999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Prosthetic and Vein Bypass with Nitinol Stents in Long Femoropopliteal Lesions.
    Kluckner M; Gratl A; Wipper SH; Hitzl W; Nierlich P; Aspalter M; Linni K; Enzmann FK
    Ann Vasc Surg; 2022 Jan; 78():272-280. PubMed ID: 34437960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and clinical implications of stent fractures of the Xpert self-expanding nitinol stent in infrainguinal arteries.
    Keo HH; Kickuth R; Diehm N; Baumgartner I; Dai-Do D
    Vasa; 2009 Feb; 38(1):47-52. PubMed ID: 19229803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial.
    Laird JR; Zeller T; Loewe C; Chamberlin J; Begg R; Schneider PA; Nanjundappa A; Bunch F; Schultz S; Harlin S; Lansky A; Jaff MR
    J Endovasc Ther; 2018 Feb; 25(1):68-78. PubMed ID: 29285955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endovascular Intervention for the Treatment of Trans-Atlantic Inter-Society Consensus (TASC) D Femoropopliteal Lesions: A Systematic Review and Meta-Analysis.
    Giannopoulos S; Lyden SP; Bisdas T; Micari A; Parikh SA; Jaff MR; Schneider PA; Armstrong EJ
    Cardiovasc Revasc Med; 2021 Jan; 22():52-65. PubMed ID: 32563709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Clinical Outcomes between Endovascular Therapy with Self-Expandable Nitinol Stent and Femoral-Popliteal Bypass for Trans-Atlantic Inter-Society Consensus II C and D Femoropopliteal Lesions.
    Okuno S; Iida O; Iida T; Takahara M; Yamaoka T; Kitano I; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Mano T
    Ann Vasc Surg; 2019 May; 57():137-143. PubMed ID: 30500627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison Between Interwoven Nitinol and Drug Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease.
    Haine A; Schmid MJ; Schindewolf M; Lenz A; Bernhard SM; Drexel H; Baumgartner I; Dopheide JF
    Eur J Vasc Endovasc Surg; 2019 Dec; 58(6):865-873. PubMed ID: 31668949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass: A paradigm shift in surgical open bypass for chronic limb-threatening ischemia.
    Kobayashi T; Hamamoto M; Okazaki T; Hasegawa M; Fujiwara T; Takahashi S
    Vascular; 2021 Dec; 29(6):905-912. PubMed ID: 33349196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.